CA
NZ
UK
AU
IND
US
…
Decoy Therapeutics Inc. focuses on advancing the peptide conjugate therapeutics through its Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology (IMP3ACT) platform that reduces the complexity of drug development and manufacturing. Its IMP3ACT platform leverages machine learning and artificial intelligence tools alongside synthesis techniques to engineer, optimize, and manufacture peptide conjugates targeting various unmet medical needs. The company focuses on building a portfolio of peptide conjugate therapeutics focusing on infectious diseases and oncology. The company was formerly known as Salarius Pharmaceuticals, Inc. and change its name to Decoy Therapeutics Inc. in January 2026. Decoy Therapeutics Inc. is based in Cambridge, Massachusetts.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Public disclosures indicate Decoy Therapeutics Inc. is an early-stage biotechnology company focused on developing decoy-based therapeutic molecules, though publicly available information is limited. Long-term growth may be driven by clinical trial readouts, regulatory approvals, strategic partnerships and successful financing, and investors may find potential upside if the company's platform achieves clinical validation.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -12.52M | -5.58M | -12.54M | -31.61M | -12.77M |
| Net income | -12.52M | -5.58M | -12.54M | -31.61M | -12.77M |
| Selling general administrative | 3.73M | 4.96M | 5.72M | 7.14M | 6.10M |
| Gross profit | -8.52M | -0.00M | -0.01M | -0.01M | 1.82M |
| Reconciled depreciation | 0.01M | 0.00M | 0.01M | 0.01M | 0.02M |
| Ebit | - | -5.73M | -12.89M | -22.98M | -12.81M |
| Ebitda | -12.61M | -5.73M | -12.88M | -22.97M | -12.79M |
| Depreciation and amortization | - | 0.00M | 0.01M | 0.01M | 0.02M |
| Operating income | -12.61M | -5.73M | -12.89M | -31.84M | -12.81M |
| Other operating expenses | 12.61M | 5.73M | 12.89M | 31.84M | 12.81M |
| Interest income | 0.10M | 0.16M | 0.35M | 0.22M | - |
| Net interest income | 0.10M | 0.16M | 0.35M | 0.22M | - |
| Total revenue | 0.00M | 0.00M | 0.00M | 0.00M | 1.84M |
| Total operating expenses | 4.10M | 5.73M | 12.89M | 31.84M | 12.81M |
| Cost of revenue | 8.52M | 0.00M | 0.01M | 0.01M | 0.02M |
| Total other income expense net | 0.10M | 0.16M | 0.35M | 0.23M | 0.04M |
| Net income from continuing ops | -12.52M | -5.58M | -12.54M | -31.61M | -12.77M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 11.06M | 3.02M | 6.59M | 14.65M | 40.83M |
| Other current assets | 0.28M | 0.55M | 0.62M | 0.80M | 0.95M |
| Total liab | 5.17M | 1.51M | 1.30M | 4.27M | 2.11M |
| Total stockholder equity | 5.89M | 1.51M | 5.29M | 10.38M | 38.72M |
| Other current liab | 1.00M | 0.35M | 0.41M | 1.41M | 0.57M |
| Common stock | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Capital stock | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Retained earnings | -94.44M | -81.92M | -76.35M | -63.81M | -32.20M |
| Good will | - | - | - | 0.00M | 8.87M |
| Cash | 10.71M | 2.43M | 5.90M | 12.11M | 29.21M |
| Total current liabilities | 5.17M | 1.51M | 1.30M | 4.27M | 2.11M |
| Current deferred revenue | 3.23M | - | - | - | - |
| Net debt | -10.71M | -2.21M | -5.61M | -12.11M | -29.21M |
| Short term debt | - | 0.22M | 0.29M | - | - |
| Short long term debt | - | 0.22M | 0.29M | - | - |
| Short long term debt total | - | 0.22M | 0.29M | - | - |
| Other stockholder equity | 100.33M | 83.44M | 81.63M | 74.19M | 70.92M |
| Total current assets | 10.99M | 2.99M | 6.52M | 14.52M | 30.16M |
| Net receivables | - | - | - | 1.61M | - |
| Accounts payable | 0.94M | 0.94M | 0.60M | 2.86M | 1.54M |
| Non currrent assets other | 0.03M | 0.04M | 0.07M | 0.13M | 0.19M |
| Non current assets total | 0.07M | 0.04M | 0.07M | 0.13M | 10.67M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total cashflows from investing activities | 0.76M | - | - | -1.50M | - |
| Net borrowings | -0.22M | -0.47M | -0.28M | 0.00M | -0.48M |
| Total cash from financing activities | 12.34M | 1.06M | 6.64M | 1.99M | 28.30M |
| Net income | -12.52M | -5.58M | -12.54M | -31.61M | -12.77M |
| Change in cash | 8.28M | -3.47M | -6.21M | -17.11M | 18.10M |
| Begin period cash flow | 2.43M | 5.90M | 12.11M | 29.21M | 11.12M |
| End period cash flow | 10.71M | 2.43M | 5.90M | 12.11M | 29.21M |
| Total cash from operating activities | -4.83M | -4.53M | -12.85M | -17.60M | -10.20M |
| Issuance of capital stock | 12.56M | 1.53M | 6.92M | 1.99M | 27.29M |
| Depreciation | 0.01M | 0.00M | 0.01M | 0.01M | 0.02M |
| Other cashflows from investing activities | -0.58M | - | 0.00M | -1.50M | - |
| Change to account receivables | - | - | 1.48M | - | 2.25M |
| Other cashflows from financing activities | 12.34M | - | - | - | 1.49M |
| Capital expenditures | 0.58M | 0.00M | 0.00M | 1.50M | 0.00M |
| Change in working capital | -1.05M | 0.77M | -0.97M | 2.37M | 2.03M |
| Stock based compensation | 0.22M | 0.27M | 0.52M | 0.80M | 0.56M |
| Other non cash items | 7.47M | 0.27M | 0.13M | 10.84M | -0.04M |
| Free cash flow | -4.83M | -4.53M | -12.85M | -19.10M | -10.20M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| DCOY Decoy Therapeutics Inc. |
-0.02 1.83% |
1.07 | - | - | 15.86 | 0.54 | 72.64 | 1.52 |
| NVO Novo Nordisk A/S |
-0.54 1.32% |
40.55 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-2.37 0.43% |
544.66 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
-2.77 0.29% |
956.64 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Decoy Therapeutics Inc. focuses on advancing the peptide conjugate therapeutics through its Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology (IMP3ACT) platform that reduces the complexity of drug development and manufacturing. Its IMP3ACT platform leverages machine learning and artificial intelligence tools alongside synthesis techniques to engineer, optimize, and manufacture peptide conjugates targeting various unmet medical needs. The company focuses on building a portfolio of peptide conjugate therapeutics focusing on infectious diseases and oncology. The company was formerly known as Salarius Pharmaceuticals, Inc. and change its name to Decoy Therapeutics Inc. in January 2026. Decoy Therapeutics Inc. is based in Cambridge, Massachusetts.
| Name | Title | Year Born |
|---|---|---|
| Mr. Mark J. Rosenblum CPA | Executive VP & CFO | 1953 |
| Mr. Frederick E. Pierce II | CEO & Director | 1962 |
| Dr. Barbara Hibner Ph.D. | Chief Scientific Officer & Director | 1961 |
| Dr. Nadeem Q. Mirza M.D., M.P.H. | Senior Vice President of Clinical Development | NA |
| Mr. Peter K. Marschel M.B.A., M.S. | Chief Business Officer | 1974 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.39%
Communication Services
-0.43%
Consumer Cyclical
-0.47%
Consumer Defensive
-0.01%
Energy
+0.05%
Financial Services
-0.37%
Financials
-0.15%
Healthcare
-1.18%
Industrials
-0.47%
Real Estate
-0.28%
Technology
-1.06%
Utilities
-0.13%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...